在有治疗和未治疗的左心室功能障碍的情况下,乳腺癌的进展
Celine Civati1, B K Goovaerts2, S Van Laere3
1Laboratory of PhysioPharmacology, University of Antwerp, Antwerp, Belgium. celine.civati@uantwerpen.be.
Cardio-oncology (London, England)
|November 13, 2025
概括
治疗心力衰竭 (HF) 和左心室 (LV) 功能障碍在患有心肌梗塞 (MI) 后的小鼠中,减少了瘤生长和转移. 特定的HF药物表现出各种抗癌作用,表明HF病理生理学影响癌症进展.
科学领域:
- 心脏病学 心脏病学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 心力衰竭 (HF) 和左心室 (LV) 功能障碍与瘤生长的增加有关.
- 治疗LV功能障碍对癌症进展的影响尚不清楚.
研究的目的:
- 为了研究HF治疗是否可以减弱瘤生长,在 post-myocardial infarction (MI) 诱导的LV功能障碍的动物模型中.
- 为了确定不同的HF药理学剂 (卡维迪洛尔,埃纳拉普利尔,恩帕格利夫洛辛) 是否对癌症进展有不同的影响.
主要方法:
- 在小鼠中诱导心肌梗塞 (MI),导致LV功能障碍.
- 减少喷射分数的小鼠接受了HF治疗或车辆.
- 注射了转移性乳腺癌细胞,并分析了瘤生长,转移和基因表达.
主要成果:
- 拉普利改变了瘤组织的转录基因. 恩帕格利弗洛辛降低了原发性瘤的生长; 卡维迪洛尔降低了肺转移.
- 这些效应是特定于LV功能障碍的小鼠,并未在对照小鼠中观察到.
- 卡维迪醇和empagliflozin恢复了瘤中抑制的IFN-γ,并增加了STAT1的表达,这表明免疫通路的参与.
结论:
- 在LV功能障碍的背景下,特定的HF治疗可以减轻癌症生长.
- 抗癌效益似乎与HF病理生理学有关,而不是药物对瘤细胞的直接作用.
- 恢复免疫信号通路可能有助于观察到的抗癌效应.
更多相关视频
相关概念视频
02:07Tumor Progression
7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
01:29Heart Failure II: Pathophysiology
695
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
695
01:30Cardiomyopathy II: Dilated Cardiomyopathy
451
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
451
01:30Heart Failure IV: Classification and Diagnostic Evaluation
305
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
305
01:29Cardiomyopathy V: Interprofessional Care
323
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
323
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
380
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
380